The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024New CM24 biomarkers data presented during the third quarter of ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the ...

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Brukinsa is a small molecule Bruton’s tyrosine kinase inhibitor drug for various blood cancers ... BeiGene’s second-largest drug by revenue, at 22% contribution, is Tevimbra, an anti-PD-1 ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

For an explanation of our use of non-GAAP financial measures refer to the "Use of Non-GAAP Financial Measures" section later ...

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...